
Please try another search
For the three months ended 31 March 2022, Dynavax Technologies Corporation revenues increased 37% to $114M. Net income increased from $891K to $32.9M. Revenues reflect CpG 1018 segment increase from $21.9M to $91.5M, HEPLISAV-B segment increase from $2.7M to $20.8M. Net income benefited from Change in fair value of warrant liabilit increase from $25.6M (expense) to $1.8M (income), Interest expense decrease of 64% to $1.7M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 113.99 | 195.07 | 108.27 | 52.77 |
Gross Profit | 74.03 | 121.06 | 48.18 | 37.92 |
Operating Income | 30.76 | 80.72 | 16.07 | 3.94 |
Net Income | 32.86 | 99.78 | -28.43 | 4.47 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 1008.98 | 1039.25 | 919.71 | 647.91 |
Total Liabilities | 721.49 | 816.87 | 852.13 | 564.53 |
Total Equity | 287.48 | 222.37 | 67.58 | 83.38 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -50.44 | 335.53 | 215.03 | 148.82 |
Cash From Investing Activities | -216.48 | 14.22 | -40.71 | -86.39 |
Cash From Financing Activities | 10.29 | 55.78 | 40.96 | 35.64 |
Net Change in Cash | -256.77 | 404.1 | 214.26 | 97.53 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review